Antimalarial drugs resistance genes of Plasmodium falciparum: a review

Ann Parasitol. 2022;68(2):215-225. doi: 10.17420/ap6802.427.

Abstract

Malaria remains the most common parasitic disease on the planet, with 229 million cases and 409,000 deaths worldwide in 2019, including 274,030 children under the age of 5. It is one of the most important infectious diseases in the world and its control is compromised by the spread of the parasite's resistance to antimalarial drugs. This study aims to review the literature of resistant Plasmodium falciparum genes over the past twenty years. One hundred and five (105) articles were collected and read while the resistance of P. falciparum was being studied. Several P. falciparum gene resistances antimalarial drugs were discovered over the past twenty years. The most recent one is the Kelch13 gene of P. falciparum (Pfkelch13) which has showed resistance to artemisinin in Asia. In Africa, this gene represents a potential candidate for resistance to artemisinin, although no resistance was reported.

Publication types

  • Review

MeSH terms

  • Antimalarials* / pharmacology
  • Antimalarials* / therapeutic use
  • Artemisinins* / pharmacology
  • Artemisinins* / therapeutic use
  • Child
  • Drug Resistance / genetics
  • Humans
  • Malaria, Falciparum* / drug therapy
  • Malaria, Falciparum* / epidemiology
  • Malaria, Falciparum* / parasitology
  • Plasmodium falciparum / genetics
  • Protozoan Proteins / genetics

Substances

  • Antimalarials
  • Artemisinins
  • Protozoan Proteins